Business Description
Coya Therapeutics Inc
NAICS : 541714
SIC : 2834
ISIN : US22407B1089
Total Employee Number:
8Description
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells (Tregs). The company's initial development programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases with high unmet medical needs.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.92 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 12.08 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 29.1 | |||||
3-Year EPS without NRI Growth Rate | 30.4 | |||||
3-Year FCF Growth Rate | 38.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 5.59 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 18.09 | |||||
9-Day RSI | 26.37 | |||||
14-Day RSI | 34.15 | |||||
3-1 Month Momentum % | 25 | |||||
6-1 Month Momentum % | 13.64 | |||||
12-1 Month Momentum % | -17.54 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 15.02 | |||||
Quick Ratio | 15.02 | |||||
Cash Ratio | 14.3 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -29.3 | |||||
Shareholder Yield % | -11 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -283.65 | |||||
Net Margin % | -266.12 | |||||
EBITDA Margin % | -283.35 | |||||
FCF Margin % | -177.86 | |||||
OCF Margin % | -177.86 | |||||
ROE % | -58.37 | |||||
ROA % | -51 | |||||
ROIC % | -2143.85 | |||||
3-Year ROIIC % | 637150 | |||||
ROC (Joel Greenblatt) % | -34967.39 | |||||
ROCE % | -60.8 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 8.61 | |||||
PB Ratio | 1.94 | |||||
Price-to-Tangible-Book | 1.94 | |||||
EV-to-EBIT | -1.98 | |||||
EV-to-Forward-EBIT | -1.36 | |||||
EV-to-EBITDA | -1.98 | |||||
EV-to-Revenue | 5.61 | |||||
EV-to-Forward-Revenue | 196.03 | |||||
EV-to-FCF | -3.15 | |||||
| Price-to-Net-Current-Asset-Value | 1.95 | |||||
| Price-to-Net-Cash | 2.06 | |||||
Earnings Yield (Greenblatt) % | -50.51 | |||||
FCF Yield % | -14.83 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:COYA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Coya Therapeutics Inc Executives
DetailsGF Value™
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 7.939 | ||
| EPS (TTM) ($) | -1.15 | ||
| Beta | 0.6606 | ||
| 3-Year Sharpe Ratio | 0.4 | ||
| 3-Year Sortino Ratio | 0.7 | ||
| Volatility % | 47.68 | ||
| 14-Day RSI | 34.15 | ||
| 14-Day ATR ($) | 0.322609 | ||
| 20-Day SMA ($) | 5.03925 | ||
| 12-1 Month Momentum % | -17.54 | ||
| 52-Week Range ($) | 3.7101 - 7.75 | ||
| Shares Outstanding (Mil) | 23.46 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Coya Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Coya Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-12 | In 107 days | ||
| Second quarter earnings results for 2026 | 2026-08-12 | In 15 days | ||
| General meeting for 2026 | 2026-06-25 12:00 | 5.32 (-1.30%) | ||
| First quarter earnings results for 2026 | 2026-05-12 | 4.18 (+1.46%) | ||
| Annual report for 2026 | 2026-03-16 | 4.53 (-5.23%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-16 | 4.53 (-5.23%) | ||
| 8th Annual Evercore Healthcare Conference | 2025-12-02 08:45 | 6.24 (-4.15%) | ||
| Third quarter earnings results for 2025 | 2025-11-12 | 6.01 (+0.67%) | ||
| Guidance call for 2025 | 2025-09-10 10:00 | 6.27 (-2.34%) | ||
| Second quarter earnings results for 2025 | 2025-08-12 | 6.15 (+2.50%) |
Show
Entries
Coya Therapeutics Inc Frequently Asked Questions
What is Coya Therapeutics Inc(COYA)'s stock price today?
The current price of COYA is $4.06. The 52 week high of COYA is $7.75 and 52 week low is $3.71.
When is next earnings date of Coya Therapeutics Inc(COYA)?
The next earnings date of Coya Therapeutics Inc(COYA) is 2026-08-12 Est..
Does Coya Therapeutics Inc(COYA) pay dividends? If so, how much?
Coya Therapeutics Inc(COYA) does not pay dividend.
Guru Commentaries on NAS:COYA
No articles.
Press Release
Articles on Coya Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers